CAPTRUST Financial Advisors
MBRX icon

CAPTRUST Financial Advisors’s Moleculin Biotech MBRX Stock Holding History

CAPTRUST Financial Advisors’s Portfolio MBRX Stock Details MBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-1
Closed -$1K – 3214
2022
Q2 		$1K Hold
1
– – ﹤0.01% 4696
2022
Q1 		$1K Hold
1
– – ﹤0.01% 4711
2021
Q4 		$1K Hold
1
– – ﹤0.01% 4596
2021
Q3 		$1K Hold
1
– – ﹤0.01% 4447
2021
Q2 		$1K Hold
1
– – ﹤0.01% 4354
2021
Q1 		$1K Hold
1
– – ﹤0.01% 4207
2020
Q4 		$2K Hold
1
– – ﹤0.01% 3131
2020
Q3 		$2K Hold
1
– – ﹤0.01% 2785
2020
Q2 		$2K Buy
+1
New +$2.37K ﹤0.01% 2614

Other funds holding MBRX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SPC
Sigma Planning Corp Ann Arbor, Michigan $3.6B AUM 24.57% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

CAPTRUST Financial Advisors's MBRX Position: Q3 2022 in Review

CAPTRUST Financial Advisors sold out of Moleculin Biotech (MBRX) in Q3 2022, closing a stake of 1 share — an estimated $1K sold.

CAPTRUST Financial Advisors first reported a position in MBRX in Q2 2020 and held it in 9 quarters. The position peaked at $2K in Q4 2020. 24 funds tracked by Wall St. Rank hold MBRX as of Q3 2022.

  • CAPTRUST Financial Advisors reported no remaining Moleculin Biotech position as of Q3 2022 after selling out during the quarter.
  • CAPTRUST Financial Advisors sold 1 Moleculin Biotech share in Q3 2022, an estimated $1K.
  • CAPTRUST Financial Advisors first reported a position in Moleculin Biotech in Q2 2020 and held it in 9 quarters.
  • CAPTRUST Financial Advisors's Moleculin Biotech position peaked at $2K in Q4 2020.
  • 24 funds tracked by Wall St. Rank held Moleculin Biotech as of Q3 2022.

Based on CAPTRUST Financial Advisors's 13F filing for Q3 2022, filed 16 Nov 2022.